Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. April 2021 00:05 ET | Quelle: Angion Biomedica Corp.

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15...
30. März 2021 16:05 ET | Quelle: Angion Biomedica Corp.

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
25. März 2021 00:05 ET | Quelle: Angion Biomedica Corp.

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
19. März 2021 00:05 ET | Quelle: Angion Biomedica Corp.

Angion Announces Partial Waiver of Certain Lock-up Restrictions

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
24. Februar 2021 00:05 ET | Quelle: Angion Biomedica Corp.

Angion to Participate in Upcoming March Investment Conferences

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
09. Februar 2021 16:10 ET | Quelle: Angion Biomedica Corp.

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization...
05. Februar 2021 08:30 ET | Quelle: Angion Biomedica Corp.

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...

Vorherige Seite